ArticleSurgical endoscopy2025
Paraesophageal hernia repair combined with Roux-en-Y gastric bypass reduces short-term hernia recurrence with added metabolic benefit in patients with BMI ≥ 35: A 15-year experience.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Obesity is not associated with increased adverse outcomes following paraesophageal hernia repair.Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity is a risk factor for paraesophageal hernias (PEH), with reported higher prevalence in patients with obesity. Similarly, higher body mass index (BMI) levels adversely affect PEH repair outcomes, with well-documented hernia recurrence rates in patients with obesity. We sought to investigate PEH recurrence in combined laparoscopic PEH repair with laparoscopic Roux-en-Y gastric bypass (LPEHr/LRYGB) vs laparoscopic PEH repair alone (LPEHr) in patients with obesity. We hypothesized that LPEHr/LRYGB is associated with reduced PEH recurrence and improved metabolic outcomes compared to LPEHr.
methodsA retrospective review of a prospectively maintained database from a single academic institution was conducted. We included patients with BMI ≥ 35, with type II, III, and IV large PEH (defined as ≥ 35% of intrathoracic stomach) operated from 1/1/2009 to 1/1/2024. Patients with previous foregut surgery or concomitant weight loss surgery other than LRYGB were excluded. The primary outcome was overall PEH recurrence. Secondary outcomes were defined by metabolic benefit, measured by reduction in BMI between the two groups, and acid reflux symptoms at time of recurrence, measured by proton pump inhibitor (PPI) use. Additionally, we looked at procedural variability in the surgeries. Statistical analysis was performed by comparing propensity-matched groups using Kaplan-Meier estimates and a Log-rank test.
resultsA total of 397 patients underwent index LPEHr/LRYGB (n = 223) or LPEHr (n = 174). After propensity matching, there were a total of 180 patients with 90 patients in each group. Median follow-up after propensity matching for LPEHr/LRYGB was 57 months vs 53 months for LPEHr. There was a significant reduction of PEH recurrence rate for the first 36 months of follow-up in patients who underwent LPEHr/LRYGB compared to LPEHr (p = 0.015); however, the recurrence rates converged subsequently and at 72 months of follow-up, the difference was no longer significant (p = 0.6). Time until reoperation between the groups was not significantly different (p = 0.447). Patients who underwent LPEHr/LRYGB had a significant reduction in BMI compared to LPEHr at follow-up (- 10.2 kg/m2 vs - 2.2 kg/m2; p < 0.001). Use of PPI at time of PEH recurrence was not significantly different between the groups (p = 0.065). While use of mesh was significantly higher in the LPEHr group (59% vs 7%; p < 0.001), use of mesh was not associated with lower PEH recurrence (p = 0.273).
conclusionPatients with obesity with a BMI ≥ 35 who underwent LPEHr/LRYGB had a significant reduction in early PEH recurrence rate for the first 36 months compared to LPEHr, in addition to significant added metabolic benefit measured by long-term reduction in BMI. The long-term PEH recurrence rate between these groups showed no difference at 72 months of follow-up and beyond.
Indexed as
Identifiers
40571796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.